SCHEMBL16703189

SCHEMBL16703189

NC(=O)c1ccncc1NC(=O)C1CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 9/20 0.53
MAPT P10636 6/20 0.53
PIK3C3 Q8NEB9 1/20 0.51
MAPK10 P53779 1/20 0.49
GSK3A P49840 2/20 0.46
IRAK4 Q9NWZ3 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.45
CYP3A4 P08684 3/20 0.45
ROCK2 O75116 3/20 0.45
ROCK1 Q13464 3/20 0.45
PKN2 Q16513 3/20 0.45
CYP2D6 P10635 2/20 0.45
RPS6KA5 O75582 2/20 0.45
LRRK2 Q5S007 2/20 0.45
TP53 P04637 2/20 0.45
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
CHUK O15111 1/20 0.45
PRKD3 O94806 1/20 0.45
CDK1 P06493 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16703135 0.86 KDM4C (0.58) GSK3BMAPT
SCHEMBL18421265 0.78 KDM4C (0.51) IRAK4
SCHEMBL29856133 0.78 GSK3B (0.68) GSK3BMAPTGSK3AROCK2ROCK1
SCHEMBL14782130 0.78 HDAC3 (0.53) GSK3BCYP3A4ROCK2ROCK1PKN2
SCHEMBL21724826 0.78 SIRT2 (0.63) PIK3C3MAPK10SIRT2TP53HDAC3
SCHEMBL18422044 0.78 IRAK4 (0.50) MAPTIRAK4SIRT2HTTGLA
SCHEMBL29601833 0.78 IRAK4 (0.50) MAPTIRAK4SIRT2HTTGLA
SCHEMBL29892972 0.76 KDM4C (0.52) IRAK4
SCHEMBL4934772 0.76 IRAK4 (0.49) MAPTIRAK4SIRT2
SCHEMBL18421392 0.76 AOC1 (0.55) TP53KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3066092-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS Bristol-Myers Squibb Company (US) 2016-09-14 EP disclosed
WO-2015069593-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-05-14 WO disclosed